Monitor the Q4 2026 earnings call for any strategic commentary from incoming CEO Gaskins regarding LINZESS growth trajectory and apraglutide STARS-2 trial progress. The transition itself is orderly and non-disruptive.
Price Chart
Executive Summary
Ironwood Pharmaceuticals announced a planned CEO transition: current CEO Thomas McCourt will retire effective December 31, 2026, and Chief Commercial Officer Tammi Gaskins will succeed him as CEO and join the Board effective January 1, 2027. The orderly succession with an internal promotion and McCourt remaining on the Board makes this a routine leadership transition with no material financial impact.
Key Facts
- CEO Thomas McCourt notified the Board of his retirement effective December 31, 2026, after 17 years at Ironwood (5 as CEO).
- Chief Commercial Officer Tammi Gaskins appointed as CEO and elected to the Board, effective January 1, 2027.
- McCourt will remain on the Board after retirement and will serve as a consultant at $10,000 per month.
- Gaskins will receive an annual base salary of $775,000, a bonus target of 75% of base salary, and equity grants totaling approximately $4,000,000 in target value ($2M RSUs + $2M PSUs).
- Board size increased from 8 to 9 directors effective January 1, 2027.
Financial Impact
No material financial impact. CEO transition is routine with an internal successor; compensation disclosed is standard for the role.
Risk Factors
- Execution risk during leadership transition, though mitigated by internal promotion and overlapping board service.
- Potential strategic shifts under new CEO, though Gaskins was instrumental in LINZESS turnaround and is expected to continue current strategy.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-116423 |
| Document: tm2627624d1_ex99-1.htm | 0001104659-26-116423 |
| Document: 0001104659-26-116423-index-headers.html | 0001104659-26-116423 |
| Document: 0001104659-26-116423-index.html | 0001104659-26-116423 |
| Document: 0001104659-26-116423.txt | 0001104659-26-116423 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | 8-K | $3.50 | awaiting T+20 | awaiting T+20 | $3.51 (+0.29%) |
Aug 6, 2026 11w ago | 8-K | $4.26 $4.29 | ▲ +0.70% | ▲ +0.10% | $3.51 (−17.61%) |
May 13, 2026 23w ago | 8-K | $3.68 $3.63 | ▼ −1.36% | ▼ −0.75% | $3.51 (−4.62%) |
May 7, 2026 24w ago | 8-K | $4.17 $3.24 | ▼ −22.30% | ▼ −25.44% | $3.51 (−15.83%) |
Feb 25, 2026 34w ago | 8-K | $3.36 $3.19 | ▲ +5.06% | ▼ −0.18% | $3.51 (−4.46%) |
Feb 23, 2026 35w ago | Insider Cluster | $3.75 $3.29 | ▲ +12.27% | ▲ +8.32% | $3.51 (+6.40%) |
Feb 23, 2026 35w ago | Insider Cluster | $3.75 $3.29 | ▲ +12.27% | ▲ +8.32% | $3.51 (+6.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers